Nov 12, 2025Low $109.18 · High $193.61Nov 12, 2026
What changed · written from our data
As of Nov 12, 2026
Belite Bio, Inc American Depositary Shares closed at $169.96 on Nov 12, up 8.99%, 12.2% below its 52-week closing high. Volume of 496.5K shares was 3.13× its 20-day average (well above normal).
Split-adjusted performance: +11.3% over one month, +13.3% over six months, +60.7% over one year.
Short interest was 1.4M shares at the Oct 30 settlement, up 8.9% from the prior report (10.0 days to cover).
What does Belite Bio, Inc American Depositary Shares do?
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
What is BLTE's market cap?
$6.84B, based on the Nov 12 close of $169.96.
About Belite Bio
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
